Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18

Cancer Research

Volumn 64, Issue 5, 2004, Pages 1751-1756

  Kramer, Gero ^a   Erdal, Hamdiye ^b   Mertens, Helena J M M ^c   Nap, Marius ^c   Mauermann, Julian ^a   Steiner, Georg ^a   Marberger, Michael ^a   Bivén, Kenneth ^b   Shoshan, Maria C ^b   Linder, Stig ^b,d  

^a UNIVERSITY OF VIENNA   (Austria)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Sittard Geleen Heerlen   (Netherlands)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOKERATIN 18; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; ESTRAMUSTINE; NAVELBINE; KERATIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CARCINOMA CELL; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; BLOOD; BREAST TUMOR; NECROSIS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; FEMALE; HUMANS; KERATINS; NECROSIS;

EID: 12144290503     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2455     Document Type: Article

References (45)

1. van Dalen, A. Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res., 16: 2345-2349, 1996.
2. Stigbrand, T. The versatility of cytokeratins as tumor markers. Tumour Biol, 22: 1-3, 2001.
3. Bjorklund, B. Tissue polypeptide antigen (TPA): biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. Antibiot. Chemother., 22: 16-31, 1978.
4. Weber, K., Osborn, M., Moll, R., Wiklund, B., and Luning, B. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J., 3: 2707-2714, 1984.
5. Rydlander, L., Ziegler, E., Bergman, T., Schoberl, E., Steiner, G., Bergman, A. C., Zetterberg, A., Marberger, M., Bjorklund, P., Skern, T., Einarsson, R., and Jornvall, H. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur. J. Biochem., 241: 309-314, 1996.
6. Rastel, D., Ramaioli, A., Cornillie, F., and Thirion, B. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur. J. Cancer, 30A: 601-606, 1994.
7. Stieber, P., Hasholzner, U., Bodenmuller, H., Nagel, D., Sunder-Plassmann, L., Dienemann, H., Meier, W., and Fateh-Moghadam, A. CYFRA 21-1. A new marker in lung cancer. Cancer (Phila.), 72: 707-713, 1993.
8. Pujol, J. L., Grenier, J., Daures, J. P., Daver, A., Pujol, H., and Michel, F. B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res., 53: 61-66, 1993.
9. Chou, C. F., Riopel, C. L., Rott, L. S., and Omary, M. B. A significant soluble keratin fraction in 'simple' epithelial cells. Lack of an apparent phosphorylation and glycosylation role in keratin solubility. J. Cell Sci., 105 (Pt 2): 433-444, 1993.
10. Ku, N. O., Liao, J., and Omary, M. B. Apoptosis generates stable fragments of human type 1 keratins. J. Biol. Chem., 272: 33197-33203, 1997.
11. Caulin, C., Salvesen, G. S., and Oshima, R. G. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Cell Biol., 138: 1379-1394, 1997.
12. Leers, M. P., Kolgen, W., Bjorklund, V., Bergman, T., Tribbick, G., Persson, B., Bjorklund, P., Ramaekers, F. C., Bjorklund, B., Nap, M., Jornvall, H., and Schutte, B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol, 187: 567-572, 1999.
13. Ku, N. O., and Omary, M. B. Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation. J. Biol. Chem., 276: 26792-26798, 2001.
14. Gion, M., Boracchi, P., Dittadi, R., Biganzoli, E., Peloso, L., Gatti, C., Paccagnella, A., Rosabian, A., Vinante, O., and Meo, S. Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis. Breast Cancer Res. Treat., 59: 211-221, 2000.
15. Sheard, M. A., Vojtesek, B., Simickova, M., and Valik, D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J. Cell Biochem., 85: 670-677, 2002.
16. Dohmoto, K., Hojo, S., Fujita, J., Yang, Y., Ueda, Y., Bandoh, S., Yamaji Y., Ohtsuki, Y., Dobashi, N., Ishida, T., and Takahara, J. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int. J. Cancer, 91: 468-473, 2001.
17. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
18. Reed, J. C. Dysregulation of apoptosis in cancer. J. Clin. Oncol., 17: 2941-2953, 1999.
19. Roninson. I. B. Tumor senescence as a determinant of drug response in vivo. Drug Resist. Update, 5: 204-208, 2002.
20. Lee, S., and Schmitt, C. A. Chemotherapy response and resistance. Curr. Opin. Genet. Dev., 13: 90-96, 2003.
21. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
22. Brown, J. M., and Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res., 59: 1391-1399, 1999.
23. Borst, P., Borst, J., and Smets, L. A. Does resistance to apoptosis affect clinical response to antitumor drugs? Drug Resist. Updat., 4: 129-131, 2001.
24. Ueno, T., Toi, M., Bivén, K., Bando, H., Ogawa, T., and Linder, S. Measurement of an apoptosis product in the sera of breast cancer patients. Eur. J. Cancer, 39: 769-774, 2003.
25. Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., Hussain, M., Kaplan, R., Myers, C., Oh, W., Petrylak, D. P., Reed, E., Roth, B., Sartor, O., Scher, H., Simons, J., Sinibaldi, V., Small, E. J., Smith, M. R., Trump, D. L., Wilding, G., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol., 17: 3461-3467, 1999.
26. Hagg, M., Biven, K., Ueno, T., Rydlander, L., Bjorklund, P., Wiman, K. G., Shoshan, M., and Linder, S. A novel high-through-put assay for screening of pro-apoptotic drugs. Investig. New Drugs, 20: 253-259, 2002.
27. Bivén, K., Erdal, H., Hägg, M., Ueno, T., Zhou, R., Lynch, M., Rowley, B., Wood, J., Zhang, C., Toi, M., Shoshan, M., and Linder, S. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis, 8: 263-268, 2003.
28. Leist, M., Single, B., Castoldi, A. F., Kuhnle, S., and Nicotera, P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med., 185: 1481-1486, 1997.
29. Martin, D. S., Spriggs, D., and Koutcher, J. A. A concomitant ATP-depleting strategy markedly enhances anticancer agent activity. Apoptosis, 6: 125-131, 2001.
30. Stuart, M. C., Damoiseaux, J. G., Frederik, P. M., Arends, J. W., and Reutelingsperger, C. P. Surface exposure of phosphatidylserine during apoptosis of rat thymocytes precedes nuclear changes. Eur J. Cell Biol., 76: 77-83, 1998.
31. Kaufmann, S. H., and Vaux, D. L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene, 22: 7414-7430, 2003.
32. Scher, H. I., Kelly, W. M., Zhang, Z. F., Ouyang, P., Sun, M., Schwartz, M., Ding, C., Wang, W., Horak, I. D., and Kremer, A. B. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J. Natl. Cancer Inst., 91: 244-251, 1999.
33. Wang, L., G., Liu, X. M., Kreis, W., and Budman, D. R. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem. Pharmacol., 55: 1427-1433, 1998.
34. Pankov, R., Umezawa, A., Maki, R., Der, C. J., Hauser, C. A., and Oshima, R. G. Oncogene activation of human keratin 18 transcription via the Ras signal transduction pathway. Proc. Natl. Acad. Sci. USA, 91: 873-877, 1994.
35. Leek, R. D., Landers, R. J., Harris, A. L., and Lewis, C. E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer, 79: 991-995, 1999.
36. Kaufmann, S. H., and Earnshaw, W. C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res., 256: 42-49, 2000.
37. Meyn, R. E., Stephens, L. C., Hunter, N. R., and Milas, L. Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas, Int. J. Cancer, 60: 725-729, 1995.
38. Van de Wiele, C., Lahorte, C., Oyen, W., Boerman, O., Goethals, I., Slegers, G., and Dierckx, R. A. Nuclear medicine imaging to predict response to radiotherapy: a review. Int. J. Radiat. Oncol. Biol. Phys., 55: 5-15, 2003.
39. Belhocine, T., Steinmetz, N., Hustinx, R., Bartsch, P., Jerusalem, G., Seidel, L., Rigo, P., and Green, A. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res., 8: 2766-2774, 2002.
40. Green, A. M., and Steinmetz, N. D. Monitoring apoptosis in real time. Cancer J., 8: 82-92, 2002.
41. Reutelingsperger, C. P., Dumont, E., Thimister, P. W., van Genderen, H., Kenis, H., van de Eijnde, S., Heidendal, G., and Hofstra, L. Visualization of cell death in vivo with the annexin A5 imaging protocol. J. Immunol. Methods, 265: 123-132, 2002.
42. Eguchi, Y., Shimizu, S., and Tsujimoto, Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res., 57: 1835-1840, 1997.
43. Teicher, B. A. Hypoxia and drug resistance. Cancer Metastasis Rev., 13: 139-168, 1994.
44. Vaupel, P., Kelleher, D. K., and Hockel, M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol., 28: 29-35, 2001.
45. Schilsky, R. L. End points in cancer clinical trials and the drug approval process. Clin. Cancer Res., 8: 935-938, 2002.